Thank you to Prof. G, MouseDoctor and the Barts MS team for letting us reach out to you about the MS-STAT2 study! Are you interested in taking part? We would love to have you involved!
Follow the link for more details and to register your interest:
MS-STAT2 – What is it?
The MS-STAT2 study is a 3 year clinical trial testing whether high dose simvastatin can slow down the rate of disability progression in SPMS. This builds upon the very positive results of our previous study, MS-STAT1:
- Simvastatin slowed down the rate of brain shrinkage (whole brain atrophy) by 43% per year
- Other benefits were also seen on disability progression and some cognitive outcomes
See here for further details: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62242-4/fulltext
What does it involve?
The 3 year study involves taking tablets once a day. Importantly, there is a 50% chance of being on the simvastatin tablets for 3 years, and 50% chance of being on placebo – nobody will know what you are taking until the end of the study. This is the only way we can be sure if the simvastatin really works. There are a total of 10 visits to hospital over the 3 years of the study so we can closely monitor your progress. We are able to compensate you for travel expenses (up to £30 per visit), and the visits can be done at any of the hospitals below:
Who can take part?
We are recruiting people with secondary progressive MS (a steady progression, rather than relapses, has been the major cause of increasing disability over the last 2 years). Other key points include:
- Age 25-65, inclusive (so you can join the study so long as you do so before your 66th birthday)
- Disability: participants experience some disability (hence things like walking and balance are often starting to be affected), but are still able to walk 20m with a frame / walker (on a very flat floor with a doctor walking with you!) (aka. EDSS 4.0-6.5 inclusive)
Unfortunately you cannot take part if any of the following applies:
- Primary progressive or relapsing remitting MS
- You are already taking a statin
- You are taking another “disease modifying drug”. If any new drugs become available on the NHS for SPMS during the course of the trial, however, being in the study will not stop you from being able to take them
If you are unsure about whether you are able to take part, the best thing to do is register your interest in the trial via the above link, and we can then discuss things with you.
How are we getting on?
We already have over 250 patients in the trial around the UK, and today we have recruited our 100th patient at UCL alone! Whilst this is great news, we still have a lot of work to do to reach our target of 1180 patients. Are you interested in joining the MS-STAT2 team?
Here’s the link again for further info and to register your interest in taking part:
If any healthcare professionals would like more information, you can email the MS-STAT2 team directly at UCLH.QSMSC@nhs.net